Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

NCT03070886 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT03070886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03070886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Lead sponsor
NRG Oncology
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
April 5, 2017
Completion date
October 31, 2030
Enrollment
612 (actual)
Sites
313

Conditions

As the registry lists them; a condition with its own page is linked.

stage i prostate adenocarcinoma ajcc v7, stage ii prostate adenocarcinoma ajcc v7, stage iii prostate adenocarcinoma ajcc v7